Schonfeld Strategic Advisors’s Roivant Sciences ROIV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$569K	Sell	16,079 -37,809	-70%	-$1.12M	﹤0.01%	1751
2026 Q1	$1.49M	Buy	+53,888	New	+$1.38M	0.01%	929
2025 Q4	–	Sell	-178,965	Closed	-$2.71M	–	2518
2025 Q3	$2.71M	Buy	178,965 +163,451	+1,054%	+$2.02M	0.02%	879
2025 Q2	$175K	Sell	15,514 -52,800	-77%	-$572K	﹤0.01%	1803
2025 Q1	$689K	Sell	68,314 -3,086	-4%	-$33.4K	﹤0.01%	1445
2024 Q4	$845K	Sell	71,400 -283,295	-80%	-$3.35M	﹤0.01%	1190
2024 Q3	$4.09M	Buy	354,695 +233,377	+192%	+$2.66M	0.03%	612
2024 Q2	$1.28M	Sell	121,318 -662,449	-85%	-$7.26M	0.01%	1093
2024 Q1	$8.26M	Buy	783,767 +699,227	+827%	+$7.54M	0.05%	445
2023 Q4	$949K	Buy	+84,540	New	+$824K	0.01%	1055
2023 Q1	–	Sell	-303,215	Closed	-$2.42M	–	2568
2022 Q4	$2.42M	Buy	+303,215	New	+$1.69M	0.02%	743
2022 Q2	–	Sell	-43,500	Closed	-$215K	–	2924
2022 Q1	$215K	Buy	+43,500	New	+$287K	﹤0.01%	1908

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Schonfeld Strategic Advisors's ROIV Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Roivant Sciences (ROIV) stake by 70% in Q2 2026, selling an estimated $1.12M and leaving 16,079 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

Schonfeld Strategic Advisors first reported a position in ROIV in Q1 2022 and has held it in 12 quarters since. The position peaked at $8.26M in Q1 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Schonfeld Strategic Advisors held 16,079 shares of Roivant Sciences worth $569K as of Q2 2026.
Schonfeld Strategic Advisors sold 37,809 Roivant Sciences shares in Q2 2026, an estimated $1.12M.
Roivant Sciences made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1751 holding.
Schonfeld Strategic Advisors first reported a position in Roivant Sciences in Q1 2022 and has held it in 12 quarters since.
Schonfeld Strategic Advisors's Roivant Sciences position peaked at $8.26M in Q1 2024.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.